Federal Register of Legislation - Australian Government

Primary content

PB 13 of 2012 Lists as made
This instrument amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) to provide for additions, deletions and changes to drugs, forms, brands, responsible person codes, and the circumstances for prescribing various pharmaceutical benefits (including authority requirements).
Administered by: Health
Registered 30 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 13 of 2012

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012
(No.2)1

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated                                          23 March 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 2).

            (2)        This Instrument may also be cited as PB 13 of 2012.

2          Commencement

            This Instrument commences on 1 April 2012.

3          Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)

            Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).



Schedule 1     Amendments

 

[1]           Schedule 1, entry for Abatacept

substitute:

Abatacept

Injection 125 mg in 1 mL single dose pre-filled syringe

Injection

Orencia

BQ

MP

C3996 C3997 C3998

P3996 C3997

4

3

 

 

 

 

 

 

MP

C3996 C3997 C3998

P3998

4

5

 

 

Powder for I.V. infusion 250 mg

Injection

Orencia

BQ

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

PB

[2]           Schedule 1, entry for Amino acids—synthetic, formula

(a)        omit:

 

Oral powder 400 g (Neocate)

Oral

Neocate

SB

MP NP

C1687 C1688 C2805 C2806 C2807 C2808 C2809 C2810

 

8

5

 

(b)           insert in the columns in the order indicated, after the entry for “Oral powder 400 g (Neocate Advance Tropical Flavour)”:

 

Oral powder 400 g (Neocate Advance Vanilla)

Oral

Neocate Advance Vanilla

SB

MP NP

C1687 C1688 C2805 C2806 C2807 C2808 C2809 C2810

 

8

5

 

[3]           Schedule 1, entry for Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and
medium chain triglycerides

(a)        omit from the column headed “Form”:           (Neocate LCP + MCT)   substitute:          (Neocate Gold)

(b)        omit from the column headed “Brand”:         Neocate LCP + MCT     substitute:          Neocate Gold

[4]           Schedule 1, entry for Amlodipine in each of the forms: Tablet 5 mg (as besylate); and Tablet 10 mg (as besylate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Amlodipine Pfizer

FZ

MP NP

 

 

30

5

 

[5]           Schedule 1, entry for Anastrozole

substitute:

Anastrozole

Tablet 1 mg

Oral

Anastrol

QA

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole-DRLA

RZ

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole-GA

GM

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole GH

GQ

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole LW

TA

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole-PS

FZ

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole RBX

RA

MP NP

C2213

 

30

5

 

 

 

 

Anastrozole Sandoz

SZ

MP NP

C2213

 

30

5

 

 

 

 

Anzole

WQ

MP NP

C2213

 

30

5

 

 

 

 

APO-Anastrozole

TX

MP NP

C2213

 

30

5

 

 

 

 

Arimidex

AP

MP NP

C2213

 

30

5

 

 

 

 

Chem mart Anastrozole

CH

MP NP

C2213

 

30

5

 

 

 

 

Terry White Chemists Anastrozole

TW

MP NP

C2213

 

30

5

 

[6]           Schedule 1, entry for Apixaban

substitute:

Apixaban

Tablet 2.5 mg

Oral

Eliquis

BQ

MP NP

C3957 C3990 C3991 C3992 C3993

P3957 P3990

20

0

 

 

 

 

 

 

MP NP

C3957 C3990 C3991 C3992 C3993

P3991 P3992

30

0

 

 

 

 

 

 

MP NP

C3957 C3990 C3991 C3992 C3993

P3993

60

0

 


[7]           Schedule 1, entry for Arsenic

omit from the column headed “Authorised Prescriber”:            See Note 1

[8]           Schedule 1, entry for Atorvastatin

substitute:

Atorvastatin

Tablet 10 mg (as calcium)

Oral

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Trovas

RA

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P3047

30

11

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P3047

30

11

 

 

 

 

Trovas

RA

MP

C1540 C3047

P3047

30

11

 

 

Tablet 20 mg (as calcium)

Oral

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Trovas

RA

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P3047

30

11

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P3047

30

11

 

 

 

 

Trovas

RA

MP

C1540 C3047

P3047

30

11

 

 

Tablet 40 mg (as calcium)

Oral

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Trovas

RA

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P3047

30

11

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P3047

30

11

 

 

 

 

Trovas

RA

MP

C1540 C3047

P3047

30

11

 

 

Tablet 80 mg (as calcium)

Oral

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Trovas

RA

MP

C1540 C3047

P1540

30

5

 

 

 

 

 

 

NP

C1540

 

30

5

 

 

 

 

Atorvastatin Pfizer

FZ

MP

C1540 C3047

P3047

30

11

 

 

 

 

Lipitor

PF

MP

C1540 C3047

P3047

30

11

 

 

 

 

Trovas

RA

MP

C1540 C3047

P3047

30

11

 

[9]           Schedule 1, entry for Azathioprine in each of the forms: Tablet 25 mg; and Tablet 50 mg

omit from the column headed “Number of Repeats” (all instances):       2              substitute:             5

[10]         Schedule 1, entry for Bevacizumab

omit from the column headed “Authorised Prescriber” (all instances):  See Note 1

[11]         Schedule 1, entry for Bisoprolol in each of the forms: Tablet containing bisoprolol fumarate 2.5 mg; Tablet containing
bisoprolol fumarate 5 mg; and Tablet containing bisoprolol fumarate 10 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

APO-Bisoprolol

TX

MP NP

C3234

 

28

5

 

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Chem mart Bisoprolol

CH

MP NP

C3234

 

28

5

 

(c)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Terry White Chemists Bisoprolol

TW

MP NP

C3234

 

28

5

 

[12]         Schedule 1, entry for Bleomycin

omit:

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

Hospira Pty Limited

HH

MP
See Note 1

C1139 C1198

 

See Note 3

See Note 3

D

substitute:

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

Bleo 15K

WQ

MP

C1139 C1198

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

C1139 C1198

 

See Note 3

See Note 3

D

[13]         Schedule 1, entry for Bortezomib

substitute:

Bortezomib

Powder for injection 3.5 mg (with any determined brand of sodium chloride injection as the required solvent)

Injection

Velcade

JC

MP

C3762 C3763 C3764 C3765 C3766 C3767

 

See Note 3

See Note 3

D

[14]         Schedule 1, entry for Carboplatin

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[15]         Schedule 1, entry for Certolizumab pegol

omit from the column headed “Circumstances Code”:

C3476

[16]         Schedule 1, entry for Cetuximab

omit from the column headed “Authorised Prescriber” (all instances):  See Note 1

[17]         Schedule 1, entry for Cisplatin

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[18]         Schedule 1, entry for Cladribine

omit from the column headed “Authorised Prescriber” (twice occurring):            See Note 1

[19]         Schedule 1, entry for Clopidogrel

omit:

 

Tablet 75 mg (as besilate)

Oral

Clopidogrel Actavis

GQ

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clopidogrel-GA

GM

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clovix 75

QA

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

substitute:

 

Tablet 75 mg (as besilate)

Oral

Clopidogrel Actavis

TA

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clopidogrel-GA

GM

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clopidogrel GH

GQ

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clopidogrel-PS

FZ

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

 

 

 

Clovix 75

QA

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 


[20]         Schedule 1, entry for Clostridium Botulinum Type A Toxin—haemagglutinin Complex

substitute:

Clostridium Botulinum Type A Toxin—haemagglutinin Complex

Lyophilised powder for I.M. injection 300 units

Injection

Dysport

IS

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Lyophilised powder for I.M. injection 500 units

Injection

Dysport

IS

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[21]         Schedule 1, entry for Cyclophosphamide

omit from the column headed “Authorised Prescriber” (all instances):  See Note 1

[22]         Schedule 1, entry for Cytarabine

omit from the column headed “Authorised Prescriber”:            See Note 1

[23]         Schedule 1, entry for Dalteparin

omit:

 

Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

 

 

P3688

30

5

 

 

Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

 

 

P3688

30

5

 

substitute:

 

Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

MP NP

 

P1148

20

3

 

 

 

 

 

 

MP NP

 

P3688

30

5

 

 

Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

MP NP

 

P1148

20

3

 

 

 

 

 

 

MP NP

 

P3688

30

5

 


[24]         Schedule 1, entry for Dasatinib

substitute:

Dasatinib

Tablet 20 mg

Oral

Sprycel

BQ

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P2769 P2770 P2771

60

2

 

 

 

 

 

 

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P3999 P4000 P4003 P4004

60

5

 

 

Tablet 50 mg

Oral

Sprycel

BQ

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P2769 P2770 P2771

60

2

 

 

 

 

 

 

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P3999 P4000 P4003 P4004

60

5

 

 

Tablet 70 mg

Oral

Sprycel

BQ

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P2769 P2770 P2771

60

2

 

 

 

 

 

 

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P3999 P4000 P4003 P4004

60

5

 

 

Tablet 100 mg

Oral

Sprycel

BQ

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P2769 P2770 P2771

30

2

 

 

 

 

 

 

MP

C2769 C2770 C2771 C3999 C4000 C4003 C4004

P3999 P4000 P4003 P4004

30

5

 


[25]         Schedule 1, entry for Docetaxel

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[26]         Schedule 1, entry for Doxorubicin

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[27]         Schedule 1, entry for Doxorubicin in each of the forms: Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial; and Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Accord Doxorubicin

WQ

MP

 

 

See Note 3

See Note 3

D

[28]         Schedule 1, entry for Doxorubicin—Pegylated Liposomal

substitute:

Doxorubicin – Pegylated Liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL

Injection

Caelyx

JC

MP

 

C1568 C1795 C1796 C3905 C3910 C3911

 

See Note 3

See Note 3

D

 

 

 

 

 

MP
See Note 1

C1828 C1829 C3348 C3349

 

4

5

D

 

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL

Injection

Caelyx

JC

MP

 

C1568 C1795 C1796 C3905 C3910 C3911

 

See Note 3

See Note 3

D

[29]         Schedule 1, entry for Epirubicin

substitute:

Epirubicin

 

Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL

Injection/
intravesical

Epiccord

WQ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Actavis 10

TA

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Ebewe

SZ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Pharmorubicin Solution

PF

MP

 

 

See Note 3

See Note 3

D


 

 

Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL

Injection/
intravesical

Epiccord

WQ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Actavis 20

TA

MP

 

 

See Note 3

See Note 3

D

 

 

 

Pharmorubicin Solution

PF

MP

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/
intravesical

Epiccord

WQ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Actavis 50

TA

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Ebewe

SZ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Kabi

PK

MP

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

 

 

See Note 3

See Note 3

D

 

 

 

Pharmorubicin Solution

PF

MP

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

Injection/
intravesical

Epirubicin Actavis 100

TA

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Ebewe

SZ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/
intravesical

DBL Epirubicin Hydrochloride Injection

HH

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epiccord

WQ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Actavis 200

TA

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Ebewe

SZ

MP

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Kabi

PK

MP

 

 

See Note 3

See Note 3

D

[30]         Schedule 1, entry for Epoprostenol

(a)        omit:

 

Powder for I.V. infusion 500 micrograms (as sodium) with diluent

Injection

Flolan

GK

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 


(b)        omit:

 

Powder for I.V. infusion 1.5 mg (as sodium) with diluent

Injection

Flolan

GK

MP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[31]         Schedule 1, entry for Etoposide

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[32]         Schedule 1, entry for Fluconazole in each of the forms: Capsule 50 mg; Capsule 100 mg; and Capsule 200 mg

omit:

 

 

 

DBL Fluconazole

HH

MP NP

C3613 C3614 C3615 C3616 C3617 C3618

 

28

5

 

[33]         Schedule 1, entry for Fludarabine

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[34]         Schedule 1, entry for Fluorouracil

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[35]         Schedule 1, entry for Fluoxetine in the form Tablet, dispersible, 20 mg (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Zactin Tablet

AF

MP NP

C1211 C1241

 

28

5

 

[36]         Schedule 1, entry for Fluoxetine in the form Capsule 20 mg (as hydrochloride)

omit:

 

 

 

Fluohexal

HX

MP NP

C1211 C1241

 

28

5

 

[37]         Schedule 1, entry for Fotemustine

omit from the column headed “Authorised Prescriber”:            See Note 1


[38]         Schedule 1, entry for Frusemide in the form Tablet 20 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Frusemide-PS

FZ

MP NP

 

 

100

1

 

[39]         Schedule 1, entry for Frusemide in the form Tablet 40 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Frusax

GN

MP NP

 

 

100

1

 

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Frusemide-PS

FZ

MP NP

 

 

100

1

 

[40]         Schedule 1, entry for Gabapentin in each of the forms: Tablet 600 mg; and Tablet 800 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Nupentin Tabs

AF

MP NP

C2664

 

100

5

 

[41]         Schedule 1, entry for Gemcitabine

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[42]         Schedule 1, entry for Gentamicin in the form Injection 80 mg (as sulfate) in 2 mL

omit:

 

 

 

Hospira Pty Limited

HH

MP NP

 

 

10

1

 

[43]         Schedule 1, entry for Glatiramer

omit from the column headed “Responsible Person”:                 SW         substitute:             CS


[44]         Schedule 1, entry for Glucose Indicator—Blood

omit:

 

Test strips, 50 (Freestyle Papillon)

For external use

Freestyle Papillon

MS

MP NP

 

 

2

5

 

 

 

 

 

 

MP

 

P3035

2

11

 

[45]         Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled syringe

(a)        omit from the column headed “Circumstances Code” (twice occurring):

C3484

(b)        omit from the column headed “Purposes Code”:

P3484

[46]         Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled pen

(a)        omit from the column headed “Circumstances Code” (twice occurring):

C3484

(b)        omit from the column headed “Purposes Code”:

P3484

[47]         Schedule 1, entry for Idarubicin

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[48]         Schedule 1, entry for Ifosfamide

omit from the column headed “Authorised Prescriber” (twice occurring):            See Note 1

[49]         Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate)

(a)        omit from the column headed “Circumstances Code” (twice occurring):

C2210

C2488

(b)        insert in each instance in numerical order:

C4007

C4008

[50]         Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate) [Max Quantity 60; Number of Repeats 5]

(a)        omit from the column headed “Purposes Code”:

P2210

P2488

(b)        insert in numerical order:

P4007

P4008

[51]         Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate)

(a)        omit from the column headed “Circumstances Code” (twice occurring):

C2210

C2488

(b)        insert in each instance in numerical order:

C4007

C4008

[52]         Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate) [Max Quantity 30; Number of Repeats 5]

(a)        omit from the column headed “Purposes Code”:

P2210

P2488

(b)        insert in numerical order:

P4007

P4008

[53]         Schedule 1, entry for Irinotecan

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[54]         Schedule 1, entry for Isotretinoin in each of the forms: Capsule 10 mg; and Capsule 20 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

APO-Isotretinoin

TX

MP

C1354

 

60

3

 


[55]         Schedule 1, entry for Letrozole

substitute:

Letrozole

Tablet 2.5 mg

Oral

APO-Letrozole

TX

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Chem mart Letrozole

CH

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Femara 2.5 mg

NV

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Femolet

AF

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Fera

QA

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letara

FZ

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole Actavis

TA

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole-DRLA

RZ

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole-GA

GM

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole generichealth

GQ

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole RBX

RA

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Letrozole Sandoz

SZ

MP NP

C1608 C2691 C2692

 

30

5

 

 

 

 

Terry White Chemists Letrozole

TW

MP NP

C1608 C2691 C2692

 

30

5

 


[56]         Schedule 1, entry for Methotrexate

omit:

 

Injection 5 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP
See Note 1

 

See Note 2

5
See Note 2

0
See Note 2

 

 

Injection 50 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP
See Note 1

 

See Note 2

5
See Note 2

5
See Note 2

 

 

 

 

Pfizer Australia Pty Ltd

PF

MP
See Note 1

 

See Note 2

5
See Note 2

5
See Note 2

 

 

Solution concentrate for I.V. infusion 500 mg in 20 mL vial

Injection

Hospira Pty Limited

HH

MP
See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 1000 mg in 10 mL vial

Injection

Hospira Pty Limited

HH

MP
See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

 

 

Methotrexate Ebewe

SZ

MP
See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 5000 mg in 50 mL vial

Injection

Methotrexate Ebewe

SZ

MP
See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

substitute:

 

Injection 5 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP

 

See Note 2

5
See Note 2

0
See Note 2

 

 

Injection 50 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP

 

See Note 2

5
See Note 2

5
See Note 2

 

 

 

 

Methaccord

WQ

MP

 

See Note 2

5
See Note 2

5
See Note 2

 

 

 

 

Pfizer Australia Pty Ltd

PF

MP

 

See Note 2

5
See Note 2

5
See Note 2

 

 

Solution concentrate for I.V. infusion 500 mg in 20 mL vial

Injection

Hospira Pty Limited

HH

MP

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 1000 mg in 10 mL vial

Injection

Hospira Pty Limited

HH

MP

 

See Note 3

See Note 3

See Note 3

PB

 

 

 

Methaccord

WQ

MP

 

See Note 3

See Note 3

See Note 3

PB

 

 

 

Methotrexate Ebewe

SZ

MP

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 5000 mg in 50 mL vial

Injection

Methotrexate Ebewe

SZ

MP

 

See Note 3

See Note 3

See Note 3

PB

[57]         Schedule 1, entry for Mitozantrone

omit from the column headed “Authorised Prescriber” (all instances):                  See Note 1

[58]         Schedule 1, entry for Mycophenolic Acid

omit:

 

Capsule containing mycophenolate mofetil 250 mg

Oral

CellCept

RO

MP

C1765 C1766

 

300

3

 

 

 

 

 

 

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

Tablet containing mycophenolate mofetil 500 mg

Oral

CellCept

RO

MP

C1765 C1766

 

150

3

 

 

 

 

 

 

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

substitute:

 

Capsule containing mycophenolate mofetil 250 mg

Oral

APO-Mycophenolate

TX

MP

C1765 C1766

 

300

3

 

 

 

 

CellCept

RO

MP

C1765 C1766

 

300

3

 

 

 

 

Ceptolate

AF

MP

C1765 C1766

 

300

3

 

 

 

 

Imulate

QA

MP

C1765 C1766

 

300

3

 

 

 

 

Mycophenolate Sandoz

SZ

MP

C1765 C1766

 

300

3

 

 

 

 

APO-Mycophenolate

TX

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

 

 

CellCept

RO

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

 

 

Ceptolate

AF

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

 

 

Imulate

QA

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

 

 

Mycophenolate Sandoz

SZ

MP
See Note 1

C1650 C1651 C3355 C3356

 

600

5

C

 

 

Tablet containing mycophenolate mofetil 500 mg

Oral

APO-Mycophenolate

TX

MP

C1765 C1766

 

150

3

 

 

 

 

CellCept

RO

MP

C1765 C1766

 

150

3

 

 

 

 

Ceptolate

AF

MP

C1765 C1766

 

150

3

 

 

 

 

Imulate

QA

MP

C1765 C1766

 

150

3

 

 

 

 

Mycophenolate Sandoz

SZ

MP

C1765 C1766

 

150

3

 

 

 

 

APO-Mycophenolate

TX

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

 

 

 

CellCept

RO

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

 

 

 

Ceptolate

AF

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

 

 

 

Imulate

QA

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

 

 

 

Mycophenolate Sandoz

SZ

MP
See Note 1

C1650 C1651 C3355 C3356

 

300

5

C

[59]         Schedule 1, after entry for Nevirapine in the form Tablet 200 mg

insert in the columns in the order indicated:

 

Tablet 400 mg (extended release)

Oral

Viramune XR

BY

MP
See Note 1

C3587 C3589 C3994 C3995

 

60

5

D

[60]         Schedule 1, entry for Nilotinib

substitute:

Nilotinib

Capsule 150 mg (as hydrochloride monohydrate)

Oral

Tasigna

NV

MP

C4005 C4006

 

120

5

 

 

Capsule 200 mg (as hydrochloride monohydrate)

Oral

Tasigna

NV

MP

C4001 C4002

 

120

5

 

[61]         Schedule 1, entry for Oestradiol

omit:

 

Transdermal patches 8 mg, 8

Transdermal

Estraderm 100

NV

MP NP

 

 

1

5

 

[62]         Schedule 1, entry for Olanzapine

omit:

Olanzapine

Tablet 2.5 mg

Oral

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 5 mg

Oral

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 7.5 mg

Oral

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 10 mg

Oral

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Wafer 5 mg

Oral

Zyprexa Zydis

LY

MP NP

C1589 C2044

 

28

5

 

 

Wafer 10 mg

Oral

Zyprexa Zydis

LY

MP NP

C1589 C2044

 

28

5

 

substitute:

Olanzapine

Tablet 2.5 mg

Oral

APO-Olanzapine

TX

MP NP

C1589 C2044

 

28

5

 

 

 

 

Chem mart Olanzapine

CH

MP NP

C1589 C2044

 

28

5

 

 

 

 

Lanzek

EL

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-DRLA

RZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-GA

GM

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-PS

FZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine RBX

RA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine Sandoz

SZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Ozin 2.5

DO

MP NP

C1589 C2044

 

28

5

 

 

 

 

Terry White Chemists Olanzapine

TW

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zylap 2.5

QA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zypine

AF

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 5 mg

Oral

APO-Olanzapine

TX

MP NP

C1589 C2044

 

28

5

 

 

 

 

Chem mart Olanzapine

CH

MP NP

C1589 C2044

 

28

5

 

 

 

 

Lanzek

EL

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-DRLA

RZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-GA

GM

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-PS

FZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine RBX

RA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine Sandoz

SZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Ozin 5

DO

MP NP

C1589 C2044

 

28

5

 

 

 

 

Terry White Chemists Olanzapine

TW

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zylap 5

QA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zypine

AF

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 7.5 mg

Oral

APO-Olanzapine

TX

MP NP

C1589 C2044

 

28

5

 

 

 

 

Chem mart Olanzapine

CH

MP NP

C1589 C2044

 

28

5

 

 

 

 

Lanzek

EL

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-DRLA

RZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-GA

GM

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-PS

FZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine RBX

RA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine Sandoz

SZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Ozin 7.5

DO

MP NP

C1589 C2044

 

28

5

 

 

 

 

Terry White Chemists Olanzapine

TW

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zylap 7.5

QA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zypine

AF

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 10 mg

Oral

APO-Olanzapine

TX

MP NP

C1589 C2044

 

28

5

 

 

 

 

Chem mart Olanzapine

CH

MP NP

C1589 C2044

 

28

5

 

 

 

 

Lanzek

EL

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-DRLA

RZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-GA

GM

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine-PS

FZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine RBX

RA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Olanzapine Sandoz

SZ

MP NP

C1589 C2044

 

28

5

 

 

 

 

Ozin 10

DO

MP NP

C1589 C2044

 

28

5

 

 

 

 

Terry White Chemists Olanzapine

TW

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zylap 10

QA

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zypine

AF

MP NP

C1589 C2044

 

28

5

 

 

 

 

Zyprexa

LY

MP NP

C1589 C2044

 

28

5

 

 

Tablet 2.5 mg (as benzoate)

Oral

Olanzapine generichealth 2.5

GQ

MP NP

C1589 C2044